Myconostica raises more capital for fungal disease tests
This article was originally published in Clinica
Executive Summary
UK diagnostic company Myconostica has secured additional series D financing from its German distributor medac Gesellschaft fuer klinische Spezialpraeparate. The investment, of which the amount was undisclosed, will be used to further develop Myconostica's pipeline of fungal infection tests. medac is a privately-held Hamburg-based company with both pharma and diagnostic interests. It is the exclusive distributor of Myconostica's products in Germany. As part of the financing, Dr Rainer Dickhardt, medac's managing director, joins the board of directors at Manchester-based Myconostica.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.